AQST — Aquestive Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00- $333.13m
- $336.79m
- $50.58m
- 29
- 27
- 78
- 41
Annual balance sheet for Aquestive Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 49.3 | 31.8 | 28 | 27.3 | 23.9 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 13.1 | 6.96 | 12.1 | 4.7 | 8.47 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Current Assets | 68.3 | 44.6 | 47.3 | 39.9 | 41 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 9.73 | 10.3 | 7.78 | 9.3 | 9.74 |
| Net Intangible Assets | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 78.5 | 62.9 | 62 | 57.1 | 57.4 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 18.6 | 21.1 | 22 | 39.5 | 18.3 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 84.6 | 111 | 144 | 176 | 164 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | -6.12 | -48.5 | -82.1 | -119 | -106 |
| Total Liabilities & Shareholders' Equity | 78.5 | 62.9 | 62 | 57.1 | 57.4 |
| Total Common Shares Outstanding |